Clinical Trial Update: Oral Iloprost for the Prevention of Lung Cancer In Former Smokers [Phase 2]

View source ↗

Summary

Phase 2 trial of oral iloprost for prevention of lung cancer in former smokers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchial Epithelial Dysplasia
• Chronic Obstructive Pulmonary Disease
• Lung Cancer

Drugs mentioned

• Oral Iloprost (iloprost)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease | Phase 2 | Status: WITHDRAWN